EE443 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine in Greece for Adults Aged ≥60 Years.

Autor:	Zarkadoulas, L1 (AUTHOR), Akratos, A2 (AUTHOR), Kotsopoulos, N3 (AUTHOR)
Zdroj:	Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS143-S143. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect